Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age

Pediatric Blood and Cancer

Volumn 54, Issue 7, 2010, Pages 1050-1052

  Shima, Haruko ^a   Miharu, Masashi ^a   Osumi, Tomoo ^a   Takahashi, Takao ^a   Shimada, Hiroyuki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Fungal infection; Plasma monitoring; Voriconazole

Indexed keywords

CYCLOSPORIN A; FENTANYL; TACROLIMUS; VINCRISTINE; VORICONAZOLE;

ABSENCE OF SIDE EFFECTS; AGE DISTRIBUTION; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SIDE EFFECT; VISUAL DISORDER;

ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MYCOSES; NEOPLASMS; PYRIMIDINES; TRIAZOLES;

EID: 77951723812     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22451     Document Type: Article

References (12)

1. Walsh T, Pappas P, Winston D, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-235. (Pubitemid 34438861)
2. Purkins L, Wood N, Greenhalgh K, et al. Voriconazole, a novel wide-spectrum triazole: Oral pharmacokinetics and safety. Br J Clin Pharmacol 2003;56:10-16. (Pubitemid 37491728)
3. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-360. (Pubitemid 351265310)
4. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415. (Pubitemid 34851833)
5. Walsh TJ, Lutsar I, Driscoll T, et al.Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21:240-248. (Pubitemid 34214142)
6. Pascual A, Nieth V, Calandra T, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007;51:137-143. (Pubitemid 46047698)
7. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-211. (Pubitemid 351269158)
8. Smith J, Safdar N, Knasinski V, et al.Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570-1572.
9. Alffenaar JW, de Vos T, Uges DR, et al. High voriconazole trough levels in relation to hepatic function: How to adjust the dosage? Br J Clin Pharmacol 2009;67:262-263.
10. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004;48:2166-2172. (Pubitemid 38691615)
11. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009;53:935-944.
12. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-571. (Pubitemid 34165316)